Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Giancarlo Comi, Gloria Dalla Costa & Lucia Moiola. (2021) Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?. Expert Review of Neurotherapeutics 21:1, pages 21-34.
Read now
Read now
Claudia Volpi, Ciriana Orabona, Antonio Macchiarulo, Roberta Bianchi, Paolo Puccetti & Ursula Grohmann. (2019) Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis. Expert Opinion on Drug Discovery 14:11, pages 1199-1212.
Read now
Read now
Gorana Capkun, Raquel Lahoz, Elisabetta Verdun, Xue Song, Weston Chen, Jonathan R. Korn, Frank Dahlke, Rita Freitas, Kathy Fraeman, Jason Simeone, Barbara H. Johnson & Beth Nordstrom. (2015) Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis. Current Medical Research and Opinion 31:5, pages 1029-1039.
Read now
Read now
Articles from other publishers (21)
Yan Song, Yan Wang, Schiffon L. Wong, Danni Yang, Manasvi Sundar & Namita Tundia. (2023) Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States. Multiple Sclerosis and Related Disorders 79, pages 105052.
Crossref
Crossref
Caroline Papeix, Giovanni Castelnovo, Emmanuelle Leray, Marc Coustans, Pierre Levy, Jean-Marc Visy, Gisela Kobelt, Fabienne Lamy, Bashar Allaf, François Heintzmann, Isabelle Chouette, Eric Raponi, Barbara Durand, Emmanuelle Grevat, Driss Kamar, Marc Debouverie, Christine Lebrun-Frenay, Abdelhakim Abdelmoumni, Mouhmmad Jamal Al Aloucy, Abdullatif Al Khedr, Amer Al Najjar Carpentier, Bernard Alonzo, Tony Altarcha, Amevi Ananivi, Géraldine Androdias, Gilles Angibaud, Marie-Sylvie Artaud-Uriot, Dominique Audry-Chaboud, Marie Barre, Philippe Barres, Rabah Benrabah, Eric Berger, François-Xavier Bergouignan, Patricia Bernady, Christophe Billy, Christian Blanchard, Mickaël Bonnan, Jean-Paul Borsotti, Catherine Bossu-Van Nieuwenhuyse, Jean-Claude Bouffeteau, Sophie Bouillaguet, Yassine Boukriche, Jean-Marc Boulesteix, Bertrand Bourre, David Brassat, Alain Bredin, Bruno Brochet, Helene Brugeilles Baguelin, Ousmane Camara, Jean-Philippe Camdessanche, William Camu, Christophe Carel, Bertrand Carlander, Olivier Casez, Giovanni Castelnovo, Marie-Pierre Chanel-Soulier, Stéphane Chapuis, Mirella Cimpoesu, Jonathan Ciron, Pierre Clavelou, Christine Clerc, Renato Colamarino, Christophe Couratier, Sylvie Courtois, Marc Coustans, Alain Creange, Antoine Danielli, Thomas De Broucker, Jérôme De Seze, Marc Debouverie, Gilles Defer, Jérôme Delorme, Béatrice Denis, Fayçal Derouiche, Philippe Devos, Anne-Marie Deyrolle, Michel Dib, Joseph Dib, Eric Diot, Emmanuelle Doury, Sophie Dufourd-Delalande, Corinne Dupel-Pottier, Patrick Dussaux, Gilles Edan, Thibault Edouard, Jean-Pierre Escaillas, Didier Ferriby, Nicolas Fouillet, Guillaume Fromager, Tsouria Gaida-Rostane, Philippe Gaida, Guillaume Gal, Guillaume Garrigues, Annick Gayou-Joyeux, Arnaud Gentil, Philippe Gerard, Julien Gere, Laurence Gignoux, Philippe Girard, Pierric Giraud, Michel Gouttard, Pierre Gras, Anne Marie Guennoc, Michel Gugenheim, Laurent Guilloton, Karim Hadjout, Patrick Hautecoeur, Yawo Hegbe, Olivier Heinzlef, Patrice Henry, Yann Herve, Jihad Hijazi, Pascale Homeyer, Bernard Huttin, Olivier Ille, Alain Jager, Laurentiu Jomir, Nabil Kardous, Agnès Kerouanton, Comlan Paul Kpade, Christophe Kubler, Pierre Labauge, François Lallement, Nicolas Landragin, David Axel Laplaud, Henda Laribi, Gilles Lavernhe, Pierre-Éric Le Biez, Françoise Le Bras, Patrick Le Coz, Christine Lebrun-Frenay, Josette Leche, Sara Julia Leder, Alain Legout, Michele Levasseur, Alberta Lorenzi-Pernot, Pierre Louchart, Fabien Louillet, Laurent Magy, Sophie Maillard, Elisabeth Maillart, Marcel Maillet-Vioud, Catherine Mallecourt-Emberger, Éric Manchon, Alexandre Mania, Laurent Martinez-Almoyna, Mikel Martinez, Serge Massengo, Dominique Maugin, Souraya Medjbeur, Gayané Meliksetyan, Michael Menassa, Dalia Meshaka-Dimitri-Boulos, Gérard Mick, Thibault Moreau, Antoine Moulignier, Isabelle Mourand, Jean-Philippe Muller, Philippe Neuschwander, Argentino Nibbio, Chantal Nifle, Jean-Bertin Nkendjuo, Ghislain Nokam Talom, Sophie Ory, Ivania Patry, Bernard Pedespan, Jean Pelletier, Delia-Gianina Pencu, Bruno Perrouty, Stéphane Peysson, Irène Popa-Coman, André Pouliquen, Christophe Prat, Adriana Prundean, Fataï Radji, Haja Tiana Rakotoharinandrasana, Lilia Razlog, Philippe Remy, Christophe Robin, Gilles Rodier, Jérôme Romero, Brigitte Roualdes, François Rouhart, Irene Ruggieri, Feras Abdul Samad, Irina Sarafiant, Stephane Schaeffer, Nicolas Schmidt, Philippe Schuermans, Nicolas Seiller, Thierry Soisson, Annie Sortais, Bruno Stankoff, Sabrina Stefanizzi-Debuc, Laurent Suchet, Jean Tardy, Gregory Taurin, Florent Thabuy, Marie Theaudin, Caroline Tilikete-Froment, Ayman Tourbah, Patricia Tourniaire, Sylvie Trefouret, Michel Vastene, Pierre Verdure, Patrick Vermersch, Frédérique Viala, Dorothée Videt-Gibou, Elisabeth Vidry, Jean-Marc Visy, Sandra Vukusic, Marc Wagner, Valery Wattier, Christophe Zaenker, François Ziegler & Jean-Médard Zola. (2022) Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. Neurology and Therapy 11:2, pages 633-658.
Crossref
Crossref
Lina H Al-Sakran, Ruth Ann Marrie, David F Blackburn, Katherine B Knox & Charity D Evans. (2020) Predictors of hospitalization in a Canadian MS population: A matched cohort study. Multiple Sclerosis and Related Disorders 41, pages 102028.
Crossref
Crossref
Farren L. Goulding, Charity D. Evans, Katherine B. Knox, Hyun J. Lim, Michael C. Levin & Sarah J. Donkers. (2019) Individualised behaviour change strategies for physical activity in multiple sclerosis (IPAC-MS): protocol for a randomised controlled trial. Trials 20:1.
Crossref
Crossref
Judith Haas, Douglas Jeffery, Diego Silva, Daniela Piani Meier, Rolf Meinert, Jeffrey Cohen & Hans-Peter Hartung. (2019) Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. Multiple Sclerosis and Related Disorders 36, pages 101335.
Crossref
Crossref
Tjalf ZiemssenMichael LangBjörn TackenbergStephan SchmidtHolger AlbrechtLuisa KlotzJudith HaasChristoph LassekC. Anne-Marie CoutoJohn A. FindlayChristian Cornelissen. (2019) Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany. Neurology Neuroimmunology & Neuroinflammation 6:3.
Crossref
Crossref
Maria K. HoutchensNatalie C. EdwardsAmy L. Phillips. (2018) Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology 91:17.
Crossref
Crossref
Marti GroenewegSara H. ForresterBeth ArnoldLorella PalazzoWeiwei ZhuPaul YoonTim Scearce. (2018) One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program. Journal of Managed Care & Specialty Pharmacy 24:5, pages 458-463.
Crossref
Crossref
Daniel Kantor, Kristen Johnson, Maria Cecilia Vieira, James Signorovitch, Nanxin Li, Wei Gao, Valerie Koo, Emilie Duchesneau & Vivian Herrera. (2018) Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis. Journal of the Neurological Sciences 388, pages 168-174.
Crossref
Crossref
Marco Puthenparampil, Chiara Cazzola, Sofia Zywicki, Lisa Federle, Erica Stropparo, Mariagiulia Anglani, Francesca Rinaldi, Paola Perini & Paolo Gallo. (2018)
NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab
versus
fingolimod efficacy in multiple sclerosis
. Therapeutic Advances in Neurological Disorders 11, pages 175628641880571.
Crossref
Crossref
Michael Munsell, Molly Frean, Joseph Menzin & Amy L. Phillips. (2017) Development and validation of a claims-based measure as an indicator for disease status in patients with multiple sclerosis treated with disease-modifying drugs. BMC Neurology 17:1.
Crossref
Crossref
T. Ziemssen, D. Rothenbacher, J. Kuhle & T. Berger. (2017) Real-world-EvidenzReal-world evidence. Der Nervenarzt 88:10, pages 1153-1158.
Crossref
Crossref
Jonathan Alsop, Jennie Medin, Christian Cornelissen, Stefan Viktor Vormfelde & Tjalf Ziemssen. (2017) Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. PLOS ONE 12:5, pages e0173353.
Crossref
Crossref
Tjalf Ziemssen, Jennie Medin, C. Anne-Marie Couto & Catherine R. Mitchell. (2017) Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. Autoimmunity Reviews 16:4, pages 355-376.
Crossref
Crossref
Tjalf Ziemssen, Jan Hillert & Helmut Butzkueven. (2016) The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine 14:1.
Crossref
Crossref
Tomas Kalincik & Helmut Butzkueven. (2016) Observational data: Understanding the real MS world. Multiple Sclerosis Journal 22:13, pages 1642-1648.
Crossref
Crossref
Damiano Baroncini, Angelo Ghezzi, Pietro O Annovazzi, Bruno Colombo, Vittorio Martinelli, Giorgio Minonzio, Lucia Moiola, Mariaemma Rodegher, Mauro Zaffaroni & Giancarlo Comi. (2016) Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Multiple Sclerosis Journal 22:10, pages 1315-1326.
Crossref
Crossref
Fredrik Nyberg, Laura Horne, Robert Morlock, Javier Nuevo, Chris Storgard, Lalitha Aiyer, Dionne M. Hines, Xavier Ansolabehere & Pierre Chevalier. (2016) Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis. Advances in Therapy 33:7, pages 1180-1198.
Crossref
Crossref
Robert Morlock, Pierre Chevalier, Laura Horne, Javier Nuevo, Chris Storgard, Lalitha Aiyer, Dionne M. Hines, Xavier Ansolabehere & Fredrik Nyberg. (2016) Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. Rheumatology and Therapy 3:1, pages 53-75.
Crossref
Crossref
Bhupendra O. Khatri. (2016) Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Therapeutic Advances in Neurological Disorders 9:2, pages 130-147.
Crossref
Crossref
Jan Dörr & Friedemann Paul. (2015) The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Current Treatment Options in Neurology 17:6.
Crossref
Crossref